Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ario Pharma Founded to Develop Novel Therapeutics for Respiratory Indications

Published: Thursday, December 12, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
Developing best in class TRPV1 antagonist for treatment of cough.

Ario Pharma Ltd has been founded to develop innovative new approaches to treat respiratory disease. Based in Cambridge, UK, Ario Pharma is a spin out from Xention Pharma Ltd, a specialist ion channel R&D company.

Ario Pharma has announced that it has successfully raised £1.9 million ($3.1 million) from an international syndicate of New Science Ventures, Forbion Capital Partners and Seroba Kernel Life Sciences.

The funding will be used to execute two separate Phase 2 trials for the Company’s lead product, XEN-D0501, in chronic idiopathic cough and cough associated with chronic obstructive pulmonary disease (COPD). XEN-D0501 is a potential best in class, orally bioavailable inhibitor of TRPV1.

Ario Pharma expects to commence the Phase 2 trials in Q1 2014. XEN-D0501 has successfully completed multiple Phase 1 studies and has been shown to be safe and well tolerated.

The Phase 2 trials will be randomized, double-blind, placebo-controlled cross-over studies and will use validated ambulatory cough monitoring technology developed by Dr. Jacky Smith from the University Hospital of South Manchester.

The Company’s Scientific Advisory Board is comprised of world-renowned UK experts in respiratory disease including Professor Maria Belvisi and Dr Mark Birrell from the National Heart and Lung Institute, Imperial College London and Professor Dave Singh and Dr Jacky Smith from the University of Manchester and University Hospital of South Manchester.

Dr John Ford, CEO of Ario Pharma, commented: “Cough is one of the most common symptoms for which patients seek medical care, and yet current medications are either poorly effective or have serious side effects. There is growing evidence for the involvement of TRP channels in driving cough reflex hypersensitivity and inflammatory responses in diseases associated with cough. We are therefore delighted to have secured investment to fund multiple Phase 2 trials that will evaluate the efficacy of XEN-D0501. We plan to build on the emerging role of TRPV1 in other respiratory diseases and to initiate discovery projects against other TRP channels that play a role in respiratory disease”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ario Pharma Strengthens Scientific Advisory Board
Professor Peter Barnes and Professor Wisia Wedzicha appointed with immediate effect.
Monday, May 12, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos